Below are the most recent publications written about "AIDS Vaccines" by people in Profiles.
-
Sealy RE, Jones BG, Surman SL, Branum K, Howlett NM, Flynn PM, Hurwitz JL. Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins. Viral Immunol. 2016 Jan-Feb; 29(1):64-70.
-
Lee S, Kapogiannis BG, Flynn PM, Rudy BJ, Bethel J, Ahmad S, Tucker D, Abdalian SE, Hoffman D, Wilson CM, Cunningham CK. Comprehension of a simplified assent form in a vaccine trial for adolescents. J Med Ethics. 2013 Jun; 39(6):410-2.
-
Wanjalla CN, Faul EJ, Gomme EA, Schnell MJ. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine. 2010 Dec 10; 29(1):130-40.
-
Sealy R, Slobod KS, Flynn P, Branum K, Surman S, Jones B, Freiden P, Lockey T, Howlett N, Hurwitz JL. Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int Rev Immunol. 2009; 28(1):49-68.
-
Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology. 2008 Dec 20; 382(2):226-38.
-
McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology. 2006 Jan 20; 344(2):363-77.
-
Zurakowski R, Teel AR. A model predictive control based scheduling method for HIV therapy. J Theor Biol. 2006 Jan 21; 238(2):368-82.
-
Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology. 2005 Jan 5; 331(1):82-93.
-
McKenna PM, Aye PP, Dietzschold B, Montefiori DC, Martin LN, Marx PA, Pomerantz RJ, Lackner A, Schnell MJ. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J Virol. 2004 Dec; 78(24):13455-9.
-
Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr. 2004 May 1; 36(1):576-87.